列沃西门丹对心脏衰竭术后低心力输出综合征的影响
Likui Fang1,2, Pengfei Zhu2, Guocan Yu2
1Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
Therapeutics and clinical risk management
|December 18, 2024
概括
莱沃西门丹的使用改善了心膜切除术后患有低心输出综合征 (LCOS) 的收缩性心膜炎患者的术后康复,减少了输管,血管压缩剂的使用和住院. 死亡率在各组之间保持相似.
科学领域:
- 心脏病学 心脏病学
- 心胸外科手术 心胸外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏切除术后的低心输出综合征 (LCOS) 具有显著的发病率和死亡率风险.
- 收缩性心膜炎是一种需要手术干预的疾病,通常导致LCOS.
- 术后LCOS的有效管理对于患者的治疗结果至关重要.
研究的目的:
- 为了评估levosimendan对手术后LCOS的影响,患者接受心周切除术,以收缩性心周炎.
- 为了比较接受levosimendan和不接受levosimendan的患者之间的康复指标和不良事件.
主要方法:
- 对32名患有收缩性心周炎的患者进行了回顾性分析,这些患者接受了心周切除术.
- 患者被分为两组:接受levosimendan的LEVO (+) 和不接受levosimendan的LEVO (-).
- 关键的术后结果包括输管持续时间,血管压缩剂使用,ICU和住院,以及死亡率进行了比较.
主要成果:
- 在LEVO (+) 组,输管时间显著缩短 (P < 0.001),血管压缩剂使用 (P = 0.006),ICU停留 (P = 0.001) 和住院 (P = 0.042).
- 在LEVO (+) 组 (P = 0.046) 中,观察到急性肝脏或损伤的病例较少.
- 没有发现30天或1年死亡率的显著差异;不良事件是可以接受的.
结论:
- 莱沃西门丹可以给患有收缩性心周炎的患者服用,这些患者在心周切除术后发展出LCOS.
- 使用levosimendan似乎可以增强术后恢复并减少并发症.
- 莱沃西门丹为改善这一患者群体的治疗结果提供了潜在的治疗选择.
相关概念视频
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:22Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
01:22Heart Failure Drugs: Diuretics
339
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
01:22Mitral Stenosis I: Introduction
1
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1